Literature DB >> 16516152

Adaptive failure to high-fat diet characterizes steatohepatitis in Alms1 mutant mice.

Todor Arsov1, Claire Z Larter, Christopher J Nolan, Nikolai Petrovsky, Christopher C Goodnow, Narcissus C Teoh, Matthew M Yeh, Geoffrey C Farrell.   

Abstract

The biochemical differences between simple steatosis, a benign liver disease, and non-alcoholic steatohepatitis, which leads to cirrhosis, are unclear. Fat aussie is an obese mouse strain with a truncating mutation (foz) in the Alms1 gene. Chow-fed female foz/foz mice develop obesity, diabetes, and simple steatosis. We fed foz/foz and wildtype mice a high-fat diet. Foz/foz mice developed serum ALT elevation and severe steatohepatitis with hepatocyte ballooning, inflammation, and fibrosis; wildtype mice showed simple steatosis. Biochemical pathways favoring hepatocellular lipid accumulation (fatty acid uptake; lipogenesis) and lipid disposal (fatty acid beta-oxidation; triglyceride egress) were both induced by high-fat feeding in wildtype but not foz/foz mice. The resulting extremely high hepatic triglyceride levels were associated with induction of mitochondrial uncoupling protein-2 and adipocyte-specific fatty acid binding protein-2, but not cytochrome P4502e1 or lipid peroxidation. In this model of metabolic syndrome, transition of steatosis to steatohepatitis was associated with hypoadiponectinemia, a mediator of hepatic fatty acid disposal pathways.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16516152     DOI: 10.1016/j.bbrc.2006.02.032

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  32 in total

1.  Fast food diet mouse: novel small animal model of NASH with ballooning, progressive fibrosis, and high physiological fidelity to the human condition.

Authors:  Michael Charlton; Anuradha Krishnan; Kimberly Viker; Schuyler Sanderson; Sophie Cazanave; Andrea McConico; Howard Masuoko; Gregory Gores
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-08-11       Impact factor: 4.052

Review 2.  The metabolic syndrome.

Authors:  Marc-Andre Cornier; Dana Dabelea; Teri L Hernandez; Rachel C Lindstrom; Amy J Steig; Nicole R Stob; Rachael E Van Pelt; Hong Wang; Robert H Eckel
Journal:  Endocr Rev       Date:  2008-10-29       Impact factor: 19.871

3.  Beyond reasonable doubt: who is the culprit in lipotoxicity in NAFLD/NASH?

Authors:  Gavin E Arteel
Journal:  Hepatology       Date:  2012-06       Impact factor: 17.425

Review 4.  Preclinical models of non-alcoholic fatty liver disease.

Authors:  Prasanna K Santhekadur; Divya P Kumar; Arun J Sanyal
Journal:  J Hepatol       Date:  2017-11-09       Impact factor: 25.083

5.  Hepatic free cholesterol accumulates in obese, diabetic mice and causes nonalcoholic steatohepatitis.

Authors:  Derrick M Van Rooyen; Claire Z Larter; W Geoffrey Haigh; Matthew M Yeh; George Ioannou; Rahul Kuver; Sum P Lee; Narci C Teoh; Geoffrey C Farrell
Journal:  Gastroenterology       Date:  2011-06-23       Impact factor: 22.682

Review 6.  New insights from rodent models of fatty liver disease.

Authors:  Jacquelyn J Maher
Journal:  Antioxid Redox Signal       Date:  2011-04-26       Impact factor: 8.401

Review 7.  Nontriglyceride hepatic lipotoxicity: the new paradigm for the pathogenesis of NASH.

Authors:  Brent A Neuschwander-Tetri
Journal:  Curr Gastroenterol Rep       Date:  2010-02

8.  TM6SF2 rs58542926 variant affects postprandial lipoprotein metabolism and glucose homeostasis in NAFLD.

Authors:  Giovanni Musso; Ugo Cipolla; Maurizio Cassader; Silvia Pinach; Francesca Saba; Franco De Michieli; Elena Paschetta; Daria Bongiovanni; Luciana Framarin; Nicola Leone; Mara Berrutti; Floriano Rosina; Stefania Corvisieri; Federica Molinaro; Antonio Sircana; Roberto Gambino
Journal:  J Lipid Res       Date:  2017-02-27       Impact factor: 5.922

9.  Hepatic effects of a methionine-choline-deficient diet in hepatocyte RXRalpha-null mice.

Authors:  Maxwell Afari Gyamfi; Yuji Tanaka; Lin He; Curtis D Klaassen; Yu-Jui Yvonne Wan
Journal:  Toxicol Appl Pharmacol       Date:  2008-10-08       Impact factor: 4.219

Review 10.  Review article: emerging anti-fibrotic therapies in the treatment of non-alcoholic steatohepatitis.

Authors:  M Noureddin; Q M Anstee; R Loomba
Journal:  Aliment Pharmacol Ther       Date:  2016-04-08       Impact factor: 8.171

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.